Article
Pharmacology & Pharmacy
Junying Yuan, Bohao Zhang, Yiran Xu, Xiaoli Zhang, Juan Song, Wenhao Zhou, Kai Hu, Dengna Zhu, Lirong Zhang, Fengmin Shao, Shusheng Zhang, Junjie Ding, Changlian Zhu
Summary: This study investigated the pharmacokinetics of low-dose lithium carbonate in young children with intellectual disability. The results showed that the lithium PK properties in young children were similar to those in older children and adults, and the proposed model can be used to optimize the dosage regimen of lithium in children.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Microbiology
Christopher M. Rubino, Anthony P. Cammarata, Anne Smits, Sebastian Schroepf, Mark Polak, Karine Litherland, Kamal Hamed
Summary: A population pharmacokinetic model for ceftobiprole in pediatric patients was developed based on data from three pediatric studies, leading to dose optimization recommendations for the treatment of hospital-acquired or community-acquired pneumonia in pediatric patients.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Review
Pediatrics
Muhammad Faisal, Willi Cawello, Stephanie Laeer
Summary: Enalapril has established safety and efficacy in adults for conditions like hypertension, heart failure, and renal failure. In pediatric patients, it is labeled for hypertension and often used off-label for heart failure. Studies on pediatric pharmacokinetics of enalapril and enalaprilat show differences in exposure levels between different age groups, highlighting the need for further research in pediatric heart failure patients.
FRONTIERS IN PEDIATRICS
(2021)
Article
Hematology
Kun Huang, Yan Wang, Yingzi Zhen, Gang Li, Xinyi Wu, Ningning Zhang, Zhenping Chen, Runhui Wu
Summary: This study revealed significant inter-individual variability in PK parameters, clinical bleeding phenotype, and joint vulnerability in patients with severe hemophilia A, highlighting the importance of considering these factors in the treatment of the disease.
THROMBOSIS RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Yulia Vugmeyster, Ana-Marija Grisic, Brigitte Brockhaus, Peter Rueckert, Mary Ruisi, Haiqing Dai, Akash Khandelwal
Summary: The study evaluated the pharmacokinetics of avelumab in pediatric patients with solid tumors. The optimal dose for pediatric patients was determined based on exposure matching with adult data, recommending a lower dose for younger or lighter patients and the adult flat dose for older or heavier patients. This information can inform future avelumab studies, including combination therapies.
CLINICAL PHARMACOKINETICS
(2022)
Article
Pharmacology & Pharmacy
Xiaohuan Du, Chenrong Huang, Ling Xue, Zheng Jiao, Min Zhu, Jie Li, Jun Lu, Peifang Xiao, Xuemei Zhou, Chenmei Mao, Zengyan Zhu, Ji Dong, Xiaoxue Liu, Zhiyao Chen, Shichao Zhang, Yiduo Ding, Shaoyan Hu, Liyan Miao
Summary: This study aimed to establish a population pharmacokinetic model for busulfan in Chinese pediatric patients undergoing hematopoietic stem cell transplantation and explore the association between busulfan exposure and clinical outcomes. The results indicated that a busulfan AUC of 950-1600 mu M x min was associated with better event-free survival.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Laura Galeotti, Francesco Ceccherini, Carmen Fucile, Valeria Marini, Antonello Di Paolo, Natalia Maximova, Francesca Mattioli
Summary: This retrospective study investigated the pharmacokinetics of DFX in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. The study found that DFX pharmacokinetics were influenced by various factors and minimum plasma concentrations were significantly correlated with drug-associated toxicities. The population pharmacokinetic model provided threshold values predictive of hepatic/renal and hematological toxicities associated with DFX.
Article
Microbiology
Antonin Praet, Laurent Bourguignon, Florence Vetele, Valentine Breant, Charlotte Genestet, Oana Dumitrescu, Anne Doleans-Jordheim, Philippe Reix, Sylvain Goutelle
Summary: This study developed nonparametric population pharmacokinetic (PK) models of tobramycin in children with CF for dosage design and model-guided therapeutic drug monitoring, with a recommended daily dose of 12.5 mg/kg optimizing efficacy and safety targets in most patients as validated through simulations.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Pediatrics
Mohamed W. Eldougdoug, Doaa M. Youssef, Amal S. El-Shal, Yasmine Ahmed Sharaf, Sridivya Raparla, Bhaskara R. Jasti, Hanan M. Elnahas
Summary: This study aimed to evaluate the pharmacokinetics of ceftriaxone in critically ill children and monitor for drug adverse effects. The results showed that the clearance of ceftriaxone is correlated with renal function and total bilirubin and liver enzymes increased during treatment. It is recommended to monitor total bilirubin and liver enzymes in ceftriaxone treatment, especially in patients with high baseline values.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Article
Pharmacology & Pharmacy
Kai Shen, Yaxin Fan, Minjie Yang, Yuancheng Chen, Jinhao Tao, Guoping Lu, Hong Zhang, Qiwei Huang, Jing Zhang
Summary: This study aimed to establish a population pharmacokinetics model for Chinese pediatric patients receiving Vancomycin and evaluate the correlation between PK/PD indices and clinical outcomes. The results showed no significant correlation between PK/PD indices and clinical efficacy, suggesting that Chinese pediatric patients may be suitable for a lower AUC(0-24)/MIC target value. Further studies are needed to explore optimal dose regimens for Chinese pediatric patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Microbiology
Mei Yang, Libo Zhao, Xiaohui Wang, Chen Sun, Hengmiao Gao, Xiaoling Wang, Suyun Qian
Summary: This study evaluated the population pharmacokinetic properties of linezolid in critically ill children and established an optimal dosage regimen based on developmental PopPK/PD model and simulation. Factors such as body weight and AST levels were found to significantly affect the variability in linezolid pharmacokinetics in the pediatric population. Dosage adjustment according to AST levels was deemed necessary for treatment success.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Pharmacology & Pharmacy
Yewei Chen, Qian Shen, Min Dong, Ye Xiong, Hong Xu, Zhiping Li
Summary: The study aimed to investigate the pharmacokinetics of rituximab in pediatric patients with FRNS/SDNS, showing a significant increase in drug clearance in this patient population. It suggests that higher doses or more frequent regimens of rituximab may be needed for optimal therapeutic effects in patients with FRNS/SDNS, warranting further clinical studies with more patients to confirm this result.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Mengmeng Jia, Qiwen Zhang, Zifei Qin, Dao Wang, Peng Liu, Jing Yang, Xiaojian Zhang
Summary: This study aimed to investigate an appropriate dosing regimen and assess the exposure-response relationships of posaconazole (PCZ) in children. The study found that the dosage of PCZ varied depending on the age and purpose of treatment in children. Lower PCZ concentrations were associated with unsuccessful prophylaxis, while higher PCZ concentrations were associated with positive clinical response in treatment. Factors such as age, inflammatory markers, liver function indicators, and co-administration with proton pump inhibitors significantly affected PCZ concentrations.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xuan Gao, Zhu-Li Bian, Xiao-Hong Qiao, Xiao-Wen Qian, Jun Li, Guo-Mei Shen, Hui Miao, Yi Yu, Jian-Hua Meng, Xiao-Hua Zhu, Jun-Ye Jiang, Jun Le, Ling Yu, Hong-Sheng Wang, Xiao-Wen Zhai
Summary: This study developed a population pharmacokinetic model of cyclosporine (CsA) in Chinese pediatric patients with acquired aplastic anemia (AA) and identified body weight and total bilirubin level as important factors affecting the pharmacokinetics of CsA.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Amedeo De Nicolo, Michele Pinon, Alice Palermiti, Antonello Nonnato, Alessandra Manca, Jacopo Mula, Silvia Catalano, Francesco Tandoi, Renato Romagnoli, Antonio D'Avolio, Pier Luigi Calvo
Summary: The study aimed to describe the concentrations and variability of tacrolimus in whole blood and peripheral blood mononuclear cells (PBMC) in pediatric patients undergoing constant immunosuppressive maintenance therapy after liver transplantation. Variability in PBMC concentrations of tacrolimus was similar to the variability in whole blood, with weight-adjusted dose and age appearing as significant predictors of concentrations in both compartments. Seasonal variation of tacrolimus concentrations was observed in whole blood but not in PBMC within the same individual patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Infectious Diseases
Didi Bury, Tom F. W. Wolfs, Rob Ter Heine, Eline W. Muilwijk, Wim J. E. Tissing, Roger J. Bruggemann
Summary: The study determined the pharmacokinetics of twice-a-week micafungin prophylaxis in paediatric leukaemic patients to provide the rationale for this approach. The simulations showed that all twice-a-week regimens resulted in adequate exposure for Candida therapy, with exposures well above those in adults.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Infectious Diseases
Lu Chen, Koen P. van Rhee, Roeland E. Wasmann, Elke H. J. Krekels, Marinus J. Wiezer, Eric P. A. van Dongen, Paul E. Verweij, Paul D. van der Linden, Roger J. Bruggemann, Catherijne A. J. Knibbe
Summary: This study aimed to assess the impact of obesity on the pharmacokinetics of oral and IV fluconazole. The results showed that obesity alters the pharmacokinetics of fluconazole, with higher clearance and volume of distribution observed in obese individuals. Male participants had a significantly larger volume of distribution compared to female participants.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Infectious Diseases
K. P. van Rhee, S. L. de Vroom, R. M. van Hest, P. D. van Der Linden, S. H. Tonino, E. Molendijk, R. A. A. Mathot, N. M. A. Blijlevens, C. A. J. Knibbe, R. J. M. Bruggemann, S. E. Geerlings
Summary: This study investigates the pharmacokinetics of ciprofloxacin after oral administration in patients with haematological malignancies and explores the impact of GI-mucositis on oral bioavailability and clearance. The study supports the use of oral ciprofloxacin as prophylaxis against Gram-negative infection in haematological patients with mild-to-moderate mucositis capable of oral intake.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Letter
Infectious Diseases
Beatrijs Mertens, Ruth Van Daele, Yves Debaveye, Joost Wauters, Christophe Vandenbriele, Roger Bruggemann, Matthias Gijsen, Isabel Spriet
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Lu Chen, Elke H. J. Krekels, Anne R. Heijnen, Catherijne A. J. Knibbe, Roger J. Brueggemann
Summary: This study aimed to characterize the pharmacokinetics, including the absolute oral bioavailability, of different formulations of posaconazole in healthy volunteers. The study found that the delayed-release tablet had higher bioavailability compared to the oral suspension, and taking the delayed-release tablet with food enhanced its absorption.
Article
Infectious Diseases
Anette Veringa, Roger J. Bruggemann, Lambert F. R. Span, Bart J. Biemond, Mark G. J. de Boer, Edwin R. van den Heuvel, Saskia K. Klein, Doris Kraemer, Monique C. Minnema, Niek H. J. Prakken, Bart J. A. Rijnders, Jesse J. Swen, Paul E. Verweij, Marielle J. Wondergem, Paula F. Ypma, Nicole Blijlevens, Jos G. W. Kosterink, Tjip S. van der Werf, Jan-Willem C. Alffenaar
Summary: This study investigated whether TDM-guided voriconazole treatment is superior to standard treatment for invasive aspergillosis. The results showed no significant difference in treatment outcome and adverse reactions between the TDM and non-TDM groups, but a higher proportion of voriconazole concentrations within the acceptable range were found in the TDM group.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
R. J. Bruggemann, G. M. Jensen, C. Lass-Florl
Summary: The discovery and formulation of liposomal amphotericin B have revolutionized the treatment of systemic fungal infections. It allows for higher drug concentrations with lower toxicity, providing an important therapeutic option. Extensive research has been conducted on its efficacy and safety against various pathogens.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Infectious Diseases
Anouk M. E. Jansen, Rob Ter Heine, J. P. Donnelly, Nicole Blijlevens, Roger J. M. Bruggemann
Summary: This study describes the pharmacokinetics of itraconazole and hydroxy-itraconazole following intravenous administration of a nanocrystal formulation in haematopoietic cell transplant recipients. The results suggest that the formulation is suitable and may be considered for repurposing.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Anouk M. E. Jansen, Beatrijs Mertens, Isabel Spriet, Paul E. Verweij, Jeroen Schouten, Joost Wauters, Yves Debaveye, Rob ter Heine, Roger J. M. Bruggemann
Summary: This study aimed to describe the pharmacokinetics of isavuconazole in critically ill patients and propose a dosage optimization strategy. The results showed that total exposure to isavuconazole was reduced and there was significant variability in protein binding in critically ill patients.
CLINICAL PHARMACOKINETICS
(2023)
Letter
Infectious Diseases
Anette Veringa, Roger J. Brueggemann, Jan -Willem C. Alffenaar
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
Lu Chen, Elke H. J. Krekels, Yalin Dong, Limei Chen, Johan A. Maertens, Nicole M. A. Blijlevens, Catherijne A. J. Knibbe, Roger J. Bruggemann
Summary: The pharmacokinetics of posaconazole in patients differ from those in healthy volunteers, with clinical characteristics and the Chinese race impacting the drug's absorption and clearance. However, there is no evidence to suggest that Chinese patients require a different dose compared to Caucasian patients.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Review
Infectious Diseases
Souha S. Kanj, Sara F. Haddad, Jacques F. Meis, Paul E. Verweij, Andreas Voss, Riina Rautemaa-Richardson, Gabriel Levy-Hara, Anuradha Chowdhary, Abdul Ghafur, Roger Bruggemann, Abhijit M. Bal, Jeroen Schouten
Summary: The detrimental effect of secondary pathogens, including invasive fungal infections, in COVID-19 patients is highlighted. The diagnosis of pulmonary fungal infections becomes more challenging during the pandemic, especially regarding radiological findings and mycology test results interpretation. Prolonged hospitalization in ICU, coupled with underlying host factors, increases vulnerability to fungal infections. The heavy workload, redeployment of untrained staff, and inconsistent supply of protective equipment make strict adherence to infection control measures difficult for healthcare workers.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
Didi Bury, Tom F. W. Wolfs, Rob ter Heine, Eline W. Muilwijk, Kim C. M. van der Elst, Wim J. E. Tissing, Roger J. M. Brueggemann
Summary: This study investigated the pharmacokinetics of isavuconazole in a pediatric cohort and found low bioavailability after nasogastric tube administration. The drug exposures were within the expected range following intravenous administration, and the pharmacokinetics of total and unbound isavuconazole were reported with a 5-fold range in the unbound fraction.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Julia W. Korzilius, Michelle Gompelman, Guus T. J. Wezendonk, Nynke G. L. Jager, Chantal P. Rovers, Roger J. M. Brueggemann, Geert J. A. Wanten
Summary: This study aimed to determine the bioavailability of orally administered antimicrobial agents commonly used for treatment in SBS patients. The results showed that the bioavailability of selected antimicrobial agents in certain SBS patients appeared to be better than expected, providing a feasible treatment option. However, therapeutic drug monitoring should be part of the treatment process to safeguard adequate exposure in all patients, due to the large observed differences between patients.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
J. W. A. Mouton, J. Raaijmakers, M. Botterblom, M. Toonen, R. ter Heine, R. L. Smeets, R. J. M. Bruggemann, L. te Brake, N. G. L. Jager
Summary: A UPLC-MS/MS method was developed to quantify unbound and total teicoplanin in human serum, and its accuracy and precision were evaluated by comparing with a QMS immunoassay. The results showed that the developed method provided accurate and precise measurement of teicoplanin concentrations, and it is now routinely used in pharmacological research and clinical practice.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
